- Home
- UDMY vs NTLA Comparison
UDMY vs NTLA Comparison
Compare UDMY & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UDMY
- NTLA
- Stock Information
- Founded
- UDMY 2009
- NTLA 2014
- Country
- UDMY United States
- NTLA United States
- Employees
- UDMY N/A
- NTLA N/A
- Industry
- UDMY Other Consumer Services
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- UDMY Real Estate
- NTLA Health Care
- Exchange
- UDMY Nasdaq
- NTLA Nasdaq
- Market Cap
- UDMY 1.1B
- NTLA 1.2B
- IPO Year
- UDMY 2021
- NTLA 2016
- Fundamental
- Price
- UDMY $7.20
- NTLA $11.51
- Analyst Decision
- UDMY Buy
- NTLA Buy
- Analyst Count
- UDMY 10
- NTLA 20
- Target Price
- UDMY $9.89
- NTLA $32.30
- AVG Volume (30 Days)
- UDMY 1.6M
- NTLA 4.2M
- Earning Date
- UDMY 10-28-2025
- NTLA 11-06-2025
- Dividend Yield
- UDMY N/A
- NTLA N/A
- EPS Growth
- UDMY N/A
- NTLA N/A
- EPS
- UDMY N/A
- NTLA N/A
- Revenue
- UDMY $795,538,000.00
- NTLA $52,857,000.00
- Revenue This Year
- UDMY $2.51
- NTLA $8.32
- Revenue Next Year
- UDMY $4.18
- NTLA N/A
- P/E Ratio
- UDMY N/A
- NTLA N/A
- Revenue Growth
- UDMY 3.93
- NTLA 14.99
- 52 Week Low
- UDMY $5.68
- NTLA $5.90
- 52 Week High
- UDMY $10.61
- NTLA $23.76
- Technical
- Relative Strength Index (RSI)
- UDMY 55.78
- NTLA 51.62
- Support Level
- UDMY $6.65
- NTLA $10.89
- Resistance Level
- UDMY $7.41
- NTLA $12.03
- Average True Range (ATR)
- UDMY 0.24
- NTLA 0.62
- MACD
- UDMY 0.05
- NTLA 0.02
- Stochastic Oscillator
- UDMY 76.40
- NTLA 39.05
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.